Novo Nordisk A/S
NVO
$66.45
$1.291.98%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.24% | 22.55% | 1.92% | 29.58% | 69.83% |
| Total Depreciation and Amortization | -87.76% | -14.08% | 42.66% | 71.31% | -33.23% |
| Total Amortization of Deferred Charges | 18.52% | -- | -- | -- | 14.80% |
| Total Other Non-Cash Items | -514.56% | 503.01% | 63.65% | -128.16% | 65.08% |
| Change in Net Operating Assets | 91.02% | -197.39% | 323.85% | 12.44% | -3,591.43% |
| Cash from Operations | 27.50% | 8.01% | 74.52% | -51.48% | 41.36% |
| Capital Expenditure | -69.44% | -109.82% | -75.90% | -82.47% | -99.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 218.96% | -19.56% | -178.06% | 742.85% | -207.65% |
| Cash from Investing | -513.58% | -59.27% | -120.49% | 160.14% | -11.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -21.97% | -103.83% | -1,254.69% | 33.68% | -58.48% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 23.26% | 60.84% | 15.57% | 45.45% | -29.47% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -17.08% | -- | -57.38% | -- |
| Other Financing Activities | -- | -- | -57.03% | 57.03% | -- |
| Cash from Financing | 460.47% | 6.38% | 230.87% | -29.29% | -38.65% |
| Foreign Exchange rate Adjustments | 439.62% | -184.00% | 163.81% | 116.91% | 73.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -164.33% | -49.03% | 591.74% | -457.13% | -6.68% |